ArticleFrontiers in pharmacology2025
Potential activity of
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Modulation of Oxidative Stress, Inflammatory Cytokines, and Mucosal Immunity by Green Synthesized Zinc Nanoparticles in Giardia Infection in Mice.Acta parasitologica · 2026Article
- Green Synthesized Zinc Oxide Nanoparticles as a Promising Adjuvant to Albendazole in the Management of Hydatid Cyst Disease: Molecular and Biochemical Insights.Acta parasitologica · 2026Article
- Effects of Astragaloside IV Combined With Metronidazole on Cyst Shedding and Mucosal Immune and Inflammatory Responses in a Murine Model of Giardiasis.Journal of parasitology research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The pharmacological treatment of Methods: Gas chromatography-mass spectrometry (GC-MS) was utilized to analyze the chemical composition of the prepared FME. The MTT colorimetric assay was employed to assess FME's Results: The primary components of FME were identified as terpinolene (78.72%), n-nonanal (4.47%), and linalool (4.35%). FME significantly reduced the viability and growth rate of Conclusion: This study's results demonstrate the extract's efficacy
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.